ATTR-02
/ Accession Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Pharmaceutical Surgery by Design: IV dosed virus ATTR‑02 enables in-tumor production of a universal bispecific T cell engager to address tumor heterogeneity
(SITC 2026)
- No abstract available
Bispecific • Heterogeneity • Surgery • Oncology
1 to 1
Of
1
Go to page
1